The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC

[1]  Navneet Singh,et al.  Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer , 2020, Current Treatment Options in Oncology.

[2]  M. Tsao,et al.  Canadian Multicentre Project on Standardization of PD-L1 22C3 Immunohistochemistry Laboratory Developed Tests for Pembrolizumab Therapy in Non-Small Cell Lung Cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  J. Mate,et al.  The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation , 2020, Applied immunohistochemistry & molecular morphology : AIMM.

[4]  Edward S. Kim,et al.  The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  N. Girard,et al.  PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  C. Dooms,et al.  Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort , 2019, Modern Pathology.

[7]  M. Copin,et al.  P2.09-17 Real-World Concordance Across Pathologists for PD-L1 Scoring in Non-Small Cell Lung Cancer: Results from a Large Nationwide Initiative , 2019, Journal of Thoracic Oncology.

[8]  S. Lam,et al.  PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer. , 2019, Lung cancer.

[9]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[10]  C. Stubbs,et al.  Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies , 2019, Modern Pathology.

[11]  M. Péoc'h,et al.  Impact of delayed fixation and decalcification on PD-L1 expression: a comparison of two clones , 2019, Virchows Archiv.

[12]  E. Thunnissen,et al.  Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen , 2019, Virchows Archiv.

[13]  A. Calvo,et al.  Programmed death–ligand 1 expression on direct Pap‐stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens , 2019, Cancer cytopathology.

[14]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[15]  A. Borczuk,et al.  Immunocytochemistry for predictive biomarker testing in lung cancer cytology , 2019, Cancer cytopathology.

[16]  Isaac E. Lloyd,et al.  Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[17]  A. Nicholson,et al.  OA03.03 Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study , 2018, Journal of Thoracic Oncology.

[18]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[19]  Hui Yu,et al.  PD‐L1 Immunohistochemistry Comparability Study in Real‐Life Clinical Samples: Results of Blueprint Phase 2 Project , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  P. Swanson,et al.  Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non–Small Cell Lung Carcinomas , 2018, Applied immunohistochemistry & molecular morphology : AIMM.

[21]  V. Prieto,et al.  Programmed death ligand 1 testing in non–small cell lung carcinoma cytology cell block and aspirate smear preparations , 2018, Cancer cytopathology.

[22]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[23]  L. Sholl,et al.  Cytologic‐histologic correlation of programmed death‐ligand 1 immunohistochemistry in lung carcinomas , 2018, Cancer cytopathology.

[24]  J. Juco,et al.  Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients , 2018, Cancer cytopathology.

[25]  Jianrong Zhang,et al.  Updated statistics of lung and bronchus cancer in United States (2018). , 2018, Journal of thoracic disease.

[26]  D. Fujimoto,et al.  Reduced Tumour Proportion Scores for Programmed Cell Death Ligand 1 in Stored Paraffin Tissue Sections. , 2018, Anticancer research.

[27]  T. Morimoto,et al.  Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  R. Trisolini,et al.  Fading With Time of PD-L1 Immunoreactivity in Non–Small Cells Lung Cancer Tissues: A Methodological Study , 2016, Applied immunohistochemistry & molecular morphology : AIMM.

[29]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[30]  J. Heymann,et al.  PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens , 2017, Cancer cytopathology.

[31]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[32]  B. Skov,et al.  Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[33]  J. Taube,et al.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.

[34]  S. Fox,et al.  Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[35]  D. Rimm,et al.  Quantitative and Pathologist-Read comparison of the Heterogeneity of Programmed Death-Ligand 1(PD-L1) expression in Non-Small Cell Lung Cancer , 2016, Modern Pathology.

[36]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[37]  Xiaoling Zhang,et al.  Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer , 2015, Applied immunohistochemistry & molecular morphology : AIMM.

[38]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.